Sativex® (use of) in Spasticity due to Multiple Sclerosis (1083)

Warning

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

Resources

Use the button below to access this item.

Access this resource

Editorial Information

Last reviewed: 24/05/2023

Next review date: 28/02/2025

Author(s): Teng Cheng Khoo.

Version: 1

Author email(s): tengcheng.khoo3@nhs.scot.

Approved By: Regional Services Clinical Governance Group

Reviewer name(s): Teng Cheng Khoo.

Document Id: 1083

Related resources

1. Sativex® oromucosal Spray Summary of Product Characteristics (last updated on eMC 24 Aug 2018). Available from https://www.medicines.org.uk/emc/product/602
2. RCP Guideline: Spasticity in adults management using botulinum toxin, 2018. Available from: http://www.rcplondon.ac.uk/guidelines-policy/spasticity-adults-management-using-botulinum-toxin
3. NICE Clinical Guideline 144: Cannabis-based medicinal products, November 2019. Available from: https://www.nice.org.uk/guidance/ng144
4. NICE Clinical Guideline 220: Multiple sclerosis in adults: management, June 2022. Available from: http://https://www.nice.org.uk/guidance/ng220